1[1]Packer M. How should physicians view heart failure? The philosophical and physiological evoluation of three conceptual models of the disease[J] .Am J Cardiol, 1993,71(9) :3 ～ 11.
2[2]Chamberlain DA (Editorial).Digitalis:Where are we now? [J].Br Heart J, 1985,54:227 ～ 233.
3[3]Furberg CD,Yusuf S (Editorial).Effect of vasodilators on survival in chronic congestive heart failure[ J ]. Am J Cardiol, 1985,55:1110 ～ 1113.
4[4]Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with ventricular dysfunction with and without congestive heart failure: A substudy of SOLVD [J]. Circulation, 1990,82:1724 ～ 1729.
5[5]Ferguson DW. Sympathetic mechanism in heart failure: Pathophysiological and pharmacological implications [ J ]. Circulation 1993,87(Suppl Ⅶ):68 ～ 75.
7[7]Osterziel KJ, Hanlein D, Willenbrock R, et al. Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure[J] .Br Herat J,1995,73:517 ～ 522.
8[8]Chevalier B, Amrani FE, Heymes C, et al. Molecular basis of regression of cardiac hypertrophy[J]. Am J Cardiol, 1994,73(10):10 ～ 17.
9[9]Packer M. The development of positive inotropic agents for chronic heart failure:How have we gone astray? [J] .J Am Coll Cardiol, 1993,22(Suppl A):119 ～ 126.
